Search results for "alternative"

showing 10 items of 1466 documents

In silico RNA-seq and experimental analyses reveal the differential expression and splicing of EPDR1 and ZNF518B genes in relation to KRAS mutations …

2016

Several drugs used for the treatment of colorectal cancer (CRC) are targeted at the epidermal growth factor receptor, but mutations in genes of the RAS family cause resistance to these drugs. Thus, extensive research is being carried out to counterbalance this resistance. The G13D mutation of KRAS is common in humans, and we previously reported that this mutation results in the epigenetic modification of hnRNP proteins, involved in RNA splicing. As aberrant splicing often results in oncogenicity, the present study aimed to identify the genes which show altered splicing patterns in connection with the G13D KRAS mutation. To accomplish this, we first carried out an in silico analysis of RNA-s…

0301 basic medicineCancer ResearchIn silicoMutation MissenseGene ExpressionNerve Tissue ProteinsBiologymedicine.disease_causeProto-Oncogene Proteins p21(ras)03 medical and health sciences0302 clinical medicinemedicineHumansProtein IsoformsComputer SimulationEpigeneticsGeneGeneticsMutationBase SequenceModels GeneticSequence Analysis RNAAlternative splicingGeneral Medicinedigestive system diseasesNeoplasm ProteinsDNA-Binding ProteinsAlternative Splicing030104 developmental biologyOncology030220 oncology & carcinogenesisRNA splicingCancer researchKRASCarcinogenesisColorectal NeoplasmsOncology reports
researchProduct

Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic leukemia via sustained NF-κB signaling

2017

The pathogenesis of chronic lymphocytic leukemia (CLL) has been linked to constitutive NF-κB activation but the underlying mechanisms are poorly understood. Here we show that alternative splicing of the negative regulator of NF-κB and tumor suppressor gene CYLD regulates the pool of CD5+ B cells through sustained canonical NF-κB signaling. Reinforced canonical NF-κB activity leads to the development of B1 cell-associated tumor formation in aging mice by promoting survival and proliferation of CD5+ B cells, highly reminiscent of human B-CLL. We show that a substantial number of CLL patient samples express sCYLD, strongly implicating a role for it in human B-CLL. We propose that our new CLL-l…

0301 basic medicineCancer ResearchTumor suppressor geneCell SurvivalRNA SplicingChronic lymphocytic leukemia2720 Hematology610 Medicine & healthBiologyCD5 Antigenslaw.inventionPathogenesisMice03 medical and health sciencesimmune system diseaseslawhemic and lymphatic diseasesmedicineAnimalsHumans10239 Institute of Laboratory Animal Science1306 Cancer ResearchGenes Tumor SuppressorGeneCell ProliferationB-LymphocytesAlternative splicingNF-kappa BUbiquitinationHematologymedicine.diseaseLeukemia Lymphocytic Chronic B-CellDeubiquitinating Enzyme CYLDLeukemia030104 developmental biologyOncologyImmunologyCancer research570 Life sciences; biologySuppressor2730 OncologyCD5Signal TransductionLeukemia
researchProduct

Fatal Liver and Bone Marrow Toxicity by Combination Treatment of Dichloroacetate and Artesunate in a Glioblastoma Multiforme Patient: Case Report and…

2016

A 52-year-old male patient was treated with standard radiochemotherapy with temozolomide for glioblastoma multiforme (GBM). After worsening of his clinical condition, further tumor-specific treatment was unlikely to be successful, and the patient seeked help from an alternative practitioner, who administered a combination of dichloroacetate (DCA) and artesunate (ART). A few days later, the patient showed clinical and laboratory signs of liver damage and bone marrow toxicity (leukopenia, thrombocytopenia). Despite successful restoration of laboratory parameters upon symptomatic treatment, the patient died 10 days after the infusion. DCA bears a well-documented hepatotoxic risk, while ART can…

0301 basic medicineCancer Researchmedicine.medical_specialtymedicine.medical_treatmentCase ReportToxicologychemotherapyGastroenterologylcsh:RC254-28203 medical and health scienceschemistry.chemical_compound0302 clinical medicineMedizinische FakultätInternal medicineadverse effectmedicineddc:610Adverse effectCancerLiver injuryChemotherapyLeukopeniaTemozolomidebusiness.industrymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensSurgeryClinical trial030104 developmental biologychemistryOncologyArtesunate030220 oncology & carcinogenesisadverse side effectsErythropoiesismedicine.symptombusinessmedicine.drugcomplementary and alternative medicine
researchProduct

Anti-Inflammatory Activity of Citrus bergamia Derivatives: Where Do We Stand?

2016

Inflammatory diseases affect a large portion of the worldwide population, and chronic inflammation is a major risk factor for several dangerous pathologies. To limit the side effects of both synthetic and biological anti-inflammatory drugs, the use of herbal medicines, nutraceuticals and food supplements has increased tremendously as alternative and/or complementary medicine to treat several pathologies, including inflammation. During the last decades, the biological properties of Citrus bergamia (bergamot) derivatives have obtained important scientific achievements, and it has been suggested their use in a context of a multitarget pharmacological strategy. Here, we present an overview of t…

0301 basic medicineCitrusnatural productsAnti-Inflammatory AgentsCitruantioxidant activityPharmaceutical SciencebergamotReviewPharmacologyAnalytical Chemistry0302 clinical medicinecomplementary and alternative medicinesDrug DiscoveryCitrus bergamiaeducation.field_of_studyTraditional medicineMedicine (all)3. Good healthAnti-Inflammatory AgentChemistry (miscellaneous)030220 oncology & carcinogenesisMolecular MedicineComplementary medicineHumanmedicine.drug_classHerbal MedicinePopulationContext (language use)Natural productAnti-inflammatoryPlant ExtractAntioxidant activity; Bergamot; Citrus bergamia; Complementary and alternative medicines; Flavonoids; Inflammation; Natural products; Anti-Inflammatory Agents; Citrus; Herbal Medicine; Humans; Inflammation; Plant Extracts; Organic Chemistrylcsh:QD241-44103 medical and health sciencesNutraceuticallcsh:Organic chemistrySettore MED/43 - Medicina LegaleBiological propertymedicineHumansPhysical and Theoretical ChemistryeducationAntioxidant activity Bergamot Citrus bergamia Complementary and alternative medicines Flavonoids Inflammation Natural products Medicine (all);Plant Extractsbusiness.industryOrganic Chemistry030104 developmental biologyComplementary and alternative medicineinflammationflavonoidsCitrus bergamiaFlavonoidSettore BIO/14 - FarmacologiabusinessMolecules
researchProduct

Introduction: Novel hybrid combinations containing synthetic or antibiotic drugs with plant-derived phenolic or terpenoid compounds

2017

Abstract Background There is a paradigm shift in chemotherapy from mono-drug therapy towards multidrug combination regimens. Natural products from medicinal plants may play an important role for the design of novel combination therapy protocols. Hypothesis We introduce the novel term “hybrid combination” for the therapeutic combination of chemically defined plant-derived constituents (e.g. phenolic or terpenoid compounds with synthetic or antibiotic drugs to increase pharmacological activity and simultaneously toxic side effects. Study design Several literature databases were screened on the combination of phenolic/terpenoid compounds with synthetic/antibiotic drugs. Results Phenolic compou…

0301 basic medicineCombination therapymedicine.drug_classAntibioticsHerb-Drug InteractionsPharmaceutical ScienceDrug resistancePharmacologyAntioxidants03 medical and health sciencesPhenolsNetwork pharmacologyDrug DiscoverymedicineHumansOrganic chemistryMedicinal plantsAntibiotic DrugsPharmacologyBiological ProductsPlants MedicinalPlant ExtractsTerpenesChemistryBiological activityTerpenoidAnti-Bacterial Agents030104 developmental biologyComplementary and alternative medicineMolecular MedicineDrug Therapy CombinationPhytomedicine
researchProduct

Cancer combination therapy of the sesquiterpenoid artesunate and the selective EGFR-tyrosine kinase inhibitor erlotinib.

2017

Abstract Background The shift from cytotoxic to targeted chemotherapy led to improved treatment outcomes in oncology. Nevertheless, many cancer patients cannot be cured from their disease because of the development of drug resistance and side effects. Purpose There is an ongoing quest for novel compounds, which raised not only the interest in natural products but also in novel combination therapy regimens. Study design In this review, we report on the inhibition epidermal growth factor receptor (EGFR) by targeted small molecules and their combination with natural products from medicinal plants. Results The combination of erlotinib with artesunate leads to synergistic inhibition of cell grow…

0301 basic medicineCombination therapymedicine.medical_treatmentPharmaceutical ScienceArtesunateDrug resistancePharmacology03 medical and health scienceschemistry.chemical_compoundErlotinib Hydrochloride0302 clinical medicineIn vivoDrug DiscoveryAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansEpidermal growth factor receptorMolecular Targeted TherapyProtein Kinase InhibitorsPharmacologyChemotherapybiologybusiness.industryCancermedicine.diseaseArtemisininsErbB Receptors030104 developmental biologyComplementary and alternative medicinechemistryArtesunate030220 oncology & carcinogenesisbiology.proteinMolecular MedicineErlotinibbusinessmedicine.drugPhytomedicine : international journal of phytotherapy and phytopharmacology
researchProduct

Prevention from radiation damage by natural products

2018

Abstract Background Radiotherapy is a mainstay of cancer treatment since decades. Ionizing radiation (IR) is used for destruction of cancer cells and shrinkage of tumors. However, the increase of radioresistance in cancer cells and radiation toxicity to normal tissues are severe concerns. The exposure to radiation generates intracellular reactive oxygen species (ROS), which leads to DNA damage by lipid peroxidation, removal of thiol groups from cellular and membrane proteins, strand breaks and base alterations. Hypothesis Plants have to deal with radiation-induced damage (UV-light of sun, other natural radiation sources). Therefore, it is worth speculating that radioprotective mechanisms ha…

0301 basic medicineCurcuminAntioxidantDNA damagemedicine.medical_treatmentPhytochemicalsPharmaceutical ScienceSilibininRadiation-Protective AgentsAscorbic AcidBiologyPharmacologyAntioxidantsLipid peroxidation03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNeoplasmsRadioresistanceStilbenesDrug DiscoverymedicineHumansRadiation InjuriesFlavonoidsPharmacologyRadiotherapyRadiochemistryPolyphenolsPlantsAscorbic acid030104 developmental biologyComplementary and alternative medicinechemistryResveratrol030220 oncology & carcinogenesisCancer cellCurcuminMolecular MedicineLipid PeroxidationReactive Oxygen SpeciesDNA DamagePhytomedicine
researchProduct

Curcumin downregulates expression of opioid-related nociceptin receptor gene (OPRL1) in isolated neuroglia cells.

2018

Abstract Background: Curcumin (CC) exerts polyvalent pharmacological actions and multi-target effects, including pain relief and anti-nociceptive activity. In combination with Boswellia serrata extract (BS), curcumin shows greater efficacy in knee osteoarthritis management, presumably due to synergistic interaction of the ingredients. Aim: To elucidate the molecular mechanisms underlying the analgesic activity of curcumin and its synergistic interaction with BS. Methods: We performed gene expression profiling by transcriptome-wide mRNA sequencing in human T98G neuroglia cells treated with CC (Curamed), BS, and the combination of CC and BS (CC-BS; Curamin), followed by interactive pathways a…

0301 basic medicineCurcuminmedicine.drug_classNarcotic AntagonistsPharmaceutical ScienceDown-RegulationPharmacologyNociceptin Receptor03 medical and health sciencesOpioid receptorCell Line TumorDrug DiscoverymedicineHumansBoswelliaReceptorPharmacologyAnalgesicsChemistryPlant ExtractsGene expression profilingAnalgesics OpioidNociceptin receptor030104 developmental biologyMRNA SequencingComplementary and alternative medicineOpioidNeuropathic painReceptors OpioidMolecular MedicineADAMTS5 ProteinSignal transductionNeurogliamedicine.drugPhytomedicine : international journal of phytotherapy and phytopharmacology
researchProduct

Probiotics and oral health : a systematic review

2017

Background Probiotics are microorganisms, mainly bacteria, which benefit the host’s health. Many studies support the role of probiotics as a contributor to gastrointestinal health, and nowadays many authors are trying to prove its influence in oral health maintenance. Objectives To review the published literature with the purpose of knowing the importance of using probiotics as a preventive and therapeutic method for oral infectious diseases management. Material and Methods An electronic search in PubMed database with the keywords “oral health AND probiotics AND dentistry” was conducted. The inclusion criteria were: randomized clinical trials (RCTs) that assess the action of any probiotic s…

0301 basic medicineCàries dentalmedicine.medical_specialtyPathologyAlternative medicineMEDLINEOral HealthMalalties periodontalsReviewOral healthDental CariesRessenyes sistemàtiques (Investigació mèdica)Odontologialaw.invention03 medical and health sciencesProbioticMedicina preventiva0302 clinical medicineOral hygieneRandomized controlled trialSystematic reviews (Medical research)lawmedicineHumansIntensive care medicineGeneral DentistryPeriodontal DiseasesRandomized Controlled Trials as TopicPreventive medicineOral Medicine and Pathologybusiness.industryIncidence (epidemiology)Probiotics030206 dentistry:CIENCIAS MÉDICAS [UNESCO]ProbiòticsHigiene bucalJadad scale030104 developmental biologySystematic reviewOtorhinolaryngologyDentistryUNESCO::CIENCIAS MÉDICASDental cariesSurgeryPeriodontal diseasebusinessMouth Diseases
researchProduct

A Pharmacological Update of Ellagic Acid.

2018

Este artículo se encuentra disponible en la página web de la revista en la siguiente URL: https://www.thieme-connect.com/products/ejournals/pdf/10.1055/a-0633-9492.pdf This is a pre-print of an article published in Ríos, JL., Giner, RM., Marín, M. and Recio, MC. (2018). A pharmacological update of ellagic acid. Planta Medica, vol. 84, n. 15, pp. 1068-1093. The final authenticated version is available online at: https://doi.org/10.1055/a-0633-9492 Este es el pre-print del siguiente artículo Ríos, JL., Giner, RM., Marín, M. and Recio, MC. (2018). A pharmacological update of ellagic acid. Planta Medica, vol. 84, n. 15, pp. 1068-1093 que se ha publicado de forma definitiva en https://doi.org/10…

0301 basic medicineEllagic acid - Pharmacokinetics.Antioxidantmedicine.medical_treatmentMetaboliteInterleukin-1betaAnti-Inflammatory AgentsPharmaceutical ScienceApoptosisPharmacologyProtective AgentsProteína quinasa.NeuroprotectionAntioxidantsAnalytical Chemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEllagic AcidGlycationDrug DiscoverymedicineHumansProtein kinases.Cell ProliferationPharmacologyMetabolic SyndromeAldose reductaseInterleukin-6Tumor Necrosis Factor-alphaMetabolismo - Trastornos.Organic ChemistryNF-kappa BLipid metabolismAtherosclerosisEllagic acid - Physiological effect.NeuroprotectionMetabolism disorder030104 developmental biologyComplementary and alternative medicinechemistryÁcido elágico - Efectos fisiológicos.Antioxidantes.Ácido elágico - Farmacocinética.030220 oncology & carcinogenesisMolecular MedicineMetabolism - Disorders.Antioxidants.Ellagic acidPlanta medica
researchProduct